Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobs, T. W.
Right arrow Articles by Schnitt, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, T. W.
Right arrow Articles by Schnitt, S. J.
Journal of Clinical Oncology, Vol 17, Issue 7 (July), 1999: 1983
© 1999 American Society for Clinical Oncology

RAPID PUBLICATIONS

Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System

Timothy W. Jacobs, Allen M. Gown, Hadi Yaziji, Melissa J. Barnes, Stuart J. Schnitt

From the Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and PhenoPath Laboratories and IRIS, Seattle, WA.

Address reprint requests to Stuart J. Schnitt, MD, Department of Pathology, Beth Israel Deaconess Medical Center–East Campus, 330 Brookline Ave, Boston, MA 02215; email sschnitt{at}caregroup harvard.edu.

ABSTRACT

PURPOSE: To evaluate the specificity of the HercepTest for Immunoenzymatic Staining (Dako Corp, Carpinteria, CA) for determining HER-2/neu protein expression in breast cancer.

MATERIALS AND METHODS: Forty-eight invasive breast cancers previously found to be HER-2/neu–negative by two different immunohistochemical (IHC) assays and not amplified for the HER-2/neu gene by fluorescence in situ hybridization were studied using the HercepTest kit. HercepTest was performed according to the manufacturer's guidelines, and the results were scored on a 0 to 3+ scale using the United States Food and Drug Administration (FDA)–approved grading system. In this system, cases scored as 2+ or 3+ are considered HER-2/neu–positive.

RESULTS: Among these 48 cases, the IHC score using the FDA-approved scoring system was 0 in four cases (8.3%), 1+ in 16 (33.3%), 2+ in 21 (43.8%), and 3+ in seven (14.6%). Therefore, 58.4% of these cases were categorized as HER-2/neu–positive, and the specificity of the HercepTest kit for HER-2/neu expression was 41.6%. However, with the use of a modified scoring system that took into account the level of staining of nonneoplastic epithelium, the specificity increased to 93.2%.

CONCLUSION: Our results indicate that the HercepTest kit, when used in accordance with the manufacturer's guidelines and the FDA-approved scoring system, results in a large proportion of breast cancers being categorized as positive for HER-2/neu protein expression and that many of these seem to be false-positives. Consideration of the level of staining of nonneoplastic epithelium resulted in improved specificity. The current FDA-approved scoring system for HercepTest results should be reevaluated before its widespread use in clinical practice.




This article has been cited by other articles:


Home page
 Ann OncolHome page
F.-C. Bidard, M.-C. Matthieu, P. Chollet, I. Raoefils, C. Abrial, J. Domont, M. Spielmann, S. Delaloge, F. Andre, and F. Penault-Llorca
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
Ann. Onc., July 1, 2008; 19(7): 1261 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R A Walker, J M S Bartlett, M Dowsett, I O Ellis, A M Hanby, B Jasani, K Miller, and S E Pinder
HER2 testing in the UK: further update to recommendations
J. Clin. Pathol., July 1, 2008; 61(7): 818 - 824.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, C. A. Rodriguez, C. Crespo, E. de Alava, et al.
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
J Natl Cancer Inst, June 4, 2008; 100(11): 805 - 814.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Di Palma, N Collins, M Bilous, A Sapino, M Mottolese, N Kapranos, F Schmitt, and J Isola
A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer
J. Clin. Pathol., June 1, 2008; 61(6): 757 - 760.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Yamada, Y. Ichikawa, S. Yamagishi, N. Momiyama, M. Ota, S. Fujii, K. Tanaka, S. Togo, S. Ohki, and H. Shimada
Amphiregulin Is a Promising Prognostic Marker for Liver Metastases of Colorectal Cancer
Clin. Cancer Res., April 15, 2008; 14(8): 2351 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ravaioli, F. Monti, M. M. Regan, F. Maffini, M. G. Mastropasqua, V. Spataro, M. Castiglione-Gertsch, I. Panzini, L. Gianni, A. Goldhirsch, et al.
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer
Ann. Onc., April 1, 2008; 19(4): 660 - 668.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Schwarz, M Rechenmacher, T Filbeck, R Knuechel, H Blaszyk, A Hartmann, and G Brockhoff
Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions
J. Clin. Pathol., March 1, 2008; 61(3): 272 - 277.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, et al.
Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia
Blood, March 1, 2008; 111(5): 2854 - 2865.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
G. Viale, M. M. Regan, M. G. Mastropasqua, F. Maffini, E. Maiorano, M. Colleoni, K. N. Price, R. Golouh, T. Perin, R. W. Brown, et al.
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
J Natl Cancer Inst, February 6, 2008; 100(3): 207 - 212.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. Cornolti, M. Ungari, M. L. Morassi, F. Facchetti, E. Rossi, D. Lombardi, and P. Nicolai
Amplification and Overexpression of HER2/neu Gene and HER2/neu Protein in Salivary Duct Carcinoma of the Parotid Gland
Arch Otolaryngol Head Neck Surg, October 1, 2007; 133(10): 1031 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Lee, W. C. Park, H. W. Yim, M. A. Lee, G. Park, and K. Y. Lee
Expression of c-erbB2, cyclin D1 and Estrogen Receptor and their Clinical Implications in the Invasive Ductal Carcinoma of the Breast
Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 708 - 714.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi
The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions
J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Verlinden, I. Vanden Bempt, G. Eelen, M. Drijkoningen, I. Verlinden, K. Marchal, C. De Wolf-Peeters, M.-R. Christiaens, L. Michiels, R. Bouillon, et al.
The E2F-Regulated Gene Chk1 Is Highly Expressed in Triple-Negative Estrogen Receptor /Progesterone Receptor /HER-2 Breast Carcinomas
Cancer Res., July 15, 2007; 67(14): 6574 - 6581.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. A. Hudis
Trastuzumab -- Mechanism of Action and Use in Clinical Practice
N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G Valabrega, F Montemurro, and M Aglietta
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann. Onc., June 1, 2007; 18(6): 977 - 984.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C. Barrett, H. Magee, D. O'Toole, S. Daly, and M. Jeffers
Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
J. Clin. Pathol., June 1, 2007; 60(6): 690 - 693.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K. L Henriksen, B. B Rasmussen, A. E Lykkesfeldt, S. Moller, B. Ejlertsen, and H. T Mouridsen
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays
J. Clin. Pathol., April 1, 2007; 60(4): 397 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Dal Lago, V. Durbecq, C. Desmedt, R. Salgado, T. Verjat, L. Lespagnard, Y. Ma, I. Veys, A. Di Leo, C. Sotiriou, et al.
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.
Mol. Cancer Ther., October 1, 2006; 5(10): 2572 - 2579.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
S Banerjee, J S Reis-Filho, S Ashley, D Steele, A Ashworth, S R Lakhani, and I E Smith
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
J. Clin. Pathol., July 1, 2006; 59(7): 729 - 735.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
N. L. Henry and D. F. Hayes
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
Oncologist, June 1, 2006; 11(6): 541 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. S. Lyall, S. R. Dundas, S. Curran, and G. I. Murray
Profiling Markers of Prognosis in Colorectal Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1184 - 1191.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Vinatzer, B. Dampier, B. Streubel, M. Pacher, M. J. Seewald, C. Stratowa, K. Kaserer, and M. Schreiber
Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization
Clin. Cancer Res., December 1, 2005; 11(23): 8348 - 8357.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
E. Li-Ning-T, R. Ronchetti, C. Torres-Cabala, and M. J. Merino
Role of Chromogenic in Situ Hybridization (CISHTM) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish
International Journal of Surgical Pathology, October 1, 2005; 13(4): 343 - 351.
[Abstract] [PDF]

Home page
 RadiologyHome page
A. Onn, D. H. Choe, R. S. Herbst, A. M. Correa, R. F. Munden, M. T. Truong, A. A. Vaporciyan, T. Isobe, M. Z. Gilcrease, and E. M. Marom
Tumor Cavitation in Stage I Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Expression and Prediction of Poor Outcome
Radiology, October 1, 2005; 237(1): 342 - 347.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
R Ainsworth, J M S Bartlett, J J Going, E A Mallon, A Forsyth, J Richmond, W Angerson, A Watters, and B Dunne
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma
J. Clin. Pathol., October 1, 2005; 58(10): 1086 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al.
Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
Clin. Cancer Res., September 15, 2005; 11(18): 6598 - 6607.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer
{alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
Z-H Xian, S-H Zhang, W-M Cong, W-Q Wu, and M-C Wu
Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma
J. Clin. Pathol., May 1, 2005; 58(5): 500 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. H. Kim, G. Ishii, K. Goto, K. Nagai, K. Tsuta, S. Shiono, J. Nitadori, T. Kodama, Y. Nishiwaki, and A. Ochiai
Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung
Clin. Cancer Res., November 1, 2004; 10(21): 7311 - 7317.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. Yaziji, T. S. Barry, and A. M. Gown
HER-2 Testing in Breast Cancer--Reply
JAMA, October 20, 2004; 292(15): 1818 - 1818.
[Full Text] [PDF]

Home page
 JAMAHome page
R. R. Tubbs and D. G. Hicks
HER-2 Testing in Breast Cancer
JAMA, October 20, 2004; 292(15): 1817 - 1818.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Arpino, S. J. Green, D. C. Allred, D. Lew, S. Martino, C. K. Osborne, and R. M. Elledge
HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study
Clin. Cancer Res., September 1, 2004; 10(17): 5670 - 5676.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Isola, M. Tanner, A. Forsyth, T. G. Cooke, A. D. Watters, and J. M. S. Bartlett
Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization
Clin. Cancer Res., July 15, 2004; 10(14): 4793 - 4798.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, J. R. Gralow, R. B. Livingston, and A. M. Gown
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
JAMA, April 28, 2004; 291(16): 1972 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. L. Wiley and L. K. Diaz
High-Quality HER-2 Testing: Setting a Standard for Oncologic Biomarker Assessment
JAMA, April 28, 2004; 291(16): 2019 - 2020.
[Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
L. K. Diaz, R. Gupta, N. Kidwai, N. Sneige, and E. L. Wiley
The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer
J. Histochem. Cytochem., April 1, 2004; 52(4): 501 - 507.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks
HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Onn, A. M. Correa, M. Gilcrease, T. Isobe, E. Massarelli, C. D. Bucana, M. S. O'Reilly, W. K. Hong, I. J. Fidler, J. B. Putnam, et al.
Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer
Clin. Cancer Res., January 1, 2004; 10(1): 136 - 143.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Nahta and F. J. Esteva
HER-2-Targeted Therapy: Lessons Learned and Future Directions
Clin. Cancer Res., November 1, 2003; 9(14): 5078 - 5084.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff
HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin
Clin. Cancer Res., November 1, 2003; 9(14): 5238 - 5243.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al.
Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status
Cancer Res., October 1, 2003; 63(19): 6523 - 6531.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Pellegrini, M. Falleni, A. Marchetti, B. Cassani, M. Miozzo, F. Buttitta, M. Roncalli, G. Coggi, and S. Bosari
HER-2/Neu Alterations in Non-Small Cell Lung Cancer: A Comprehensive Evaluation by Real Time Reverse Transcription-PCR, Fluorescence in Situ Hybridization, and Immunohistochemistry
Clin. Cancer Res., September 1, 2003; 9(10): 3645 - 3652.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
P. Lal, P. A. Salazar, M. Ladanyi, and B. Chen
Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification
J. Mol. Diagn., August 1, 2003; 5(3): 155 - 159.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al.
A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers
J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
E. M. Brey, Z. Lalani, C. Johnston, M. Wong, L. V. McIntire, P. J. Duke, and C. W. Patrick Jr.
Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification
J. Histochem. Cytochem., May 1, 2003; 51(5): 575 - 584.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein, L. N. Harris, R. Gelman, S. C. Lester, R. A. Nunes, C. M. Kaelin, L. M. Parker, L. W. Ellisen, I. Kuter, M. A. Gadd, et al.
Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study
J. Clin. Oncol., January 1, 2003; 21(1): 46 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Di Lorenzo, G. Tortora, F. P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, M. D'Armiento, M. De Laurentiis, S. De Placido, G. Catalano, et al.
Expression of Epidermal Growth Factor Receptor Correlates with Disease Relapse and Progression to Androgen-independence in Human Prostate Cancer
Clin. Cancer Res., November 1, 2002; 8(11): 3438 - 3444.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. S. Bernard and C. T. Wittwer
Real-Time PCR Technology for Cancer Diagnostics
Clin. Chem., August 1, 2002; 48(8): 1178 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein
Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens
J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
W. K. Funkhouser and K. Kaiser-Rogers
Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma
Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 349 - 358.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. I. Pritchard
Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?
J. Clin. Oncol., September 15, 2001; 19(18): 3795 - 3797.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Ellis, A. Coop, B. Singh, L. Mauriac, A. Llombert-Cussac, F. Janicke, W. R. Miller, D. B. Evans, M. Dugan, C. Brady, et al.
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1- and/or ErbB-2-Positive, Estrogen Receptor-Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
J. Clin. Oncol., September 15, 2001; 19(18): 3808 - 3816.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Osman, H. I. Scher, M. Drobnjak, D. Verbel, M. Morris, D. Agus, J. S. Ross, and C. Cordon-Cardo
HER-2/neu (p185neu) Protein Expression in the Natural or Treated History of Prostate Cancer
Clin. Cancer Res., September 1, 2001; 7(9): 2643 - 2647.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Brabender, K. D. Danenberg, R. Metzger, P. M. Schneider, J. Park, D. Salonga, A. H. Holscher, and P. V. Danenberg
Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with Survival
Clin. Cancer Res., July 1, 2001; 7(7): 1850 - 1855.
[Abstract] [Full Text] [PDF]